Erasca seeks $550M in public offering to fund KRAS drug development
read at Endpoints ↗DealNeutral
Erasca announced a public offering targeting $550 million to advance its KRAS-targeted drug program. The biotech said the capital will support ongoing research and potential clinical trials for its pipeline.
Summit Therapeutics disclosed the sale of an antibiotic, though details of the transaction were not provided. The brief also referenced subcutaneous Leqembi, WuXi AppTec and Q32 Bio, indicating broader industry activity.
The offering reflects continued investor interest in KRAS therapeutics, a high priority area for oncology drug development.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Erasca's $550M offering; Summit sells an antibiotic”
read at Endpoints ↗72 words · retrieved Jul 14
comments(0)
5-min edit window · permanent after that